Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
23 hedge funds and large institutions have $3.66M invested in Vyant Bio, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
12% less funds holding
Funds holding: 26 → 23 (-3)
53% less capital invested
Capital invested by funds: $7.88M → $3.66M (-$4.21M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$107K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$44K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$41.3K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$41.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$384K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$344K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$52.8K |
| 4 |
VF
Virtu Financial
New York
|
-$49K |
| 5 |
HF
HRT Financial
New York
|
-$43K |
VYNT Hedge Fund Activity: Q2 2018 in Review
23 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2018, worth a combined $3.66M — down 53% from $7.88M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VYNT and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $107K. The largest seller was Stonepine Capital Management, cutting an estimated $384K.
- 23 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2018, down from 26 in Q1 2018.
- Funds reported $3.66M of Vyant Bio, Inc. Common Stock stock for Q2 2018, down 53% quarter-over-quarter.
- 2 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2018 and 5 closed out, a net change of -3 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q2 2018 was Renaissance Technologies, an estimated $107K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2018 was Stonepine Capital Management, an estimated $384K sold.
Based on aggregated 13F filings for Q2 2018.